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Abstract: Stability and removal of anti-inflammatory dexamethasone sodium phosphate (DSP), anti-anxiety drug diazepam (valium) and 
spironolactone (SP) from wastewater produced at Al-Quds University Campus were investigated. Kinetic studies in both pure water (abiotic 
degradation) and in sludge (biodegradability) at room temperature were investigated. They demonstrated that DSP underwent degradation to 
its hydrolytic derivative, simply named dexamethasone, in both media. The first order hydrolysis rate of DSP in activated sludge at 25°C 
(3.80×10-6 s-1) was about 12-fold greater than in pure water (3.25×10-7 s-1). Diazepam showed high chemical stability toward degradation in 
pure water, and underwent faster biodegradation in sludge providing two main degradation products. The degradation reactions in sludge and 
pure water showed first order kinetics with rate constant values of 2.6 × 10-7 s-1 and 9.08 × 10-8 s-1, respectively. The potassium-sparing 
diuretic (water pill) SP underwent degradation to its hydrolytic derivative, canrenone, in both media. The first order hydrolysis rate of SP in 
activated sludge at 25°C (3.80×10-5 s-1) was about 49-fold greater than in pure water (7.4×10-7 s-1). 
The overall performance of WWTP was also assessed showing that 90% of spiked DSP and SP were removed together with its newly identified 
metabolites. WWTP also showed that UF and RO were relatively sufficient in removing spiked diazepam to a safe level. In order to check for 
different tools to be used instead of ultra-filtration membranes, the effectiveness of adsorption and filtration by micelle-clay preparation for 
removing DSP was ascertained in comparison with activated charcoal. Batch adsorption in aqueous suspensions of the micelle-clay composite 
and activated carbon was well described by Langmuir isotherms showing the best results for micelle-clay material. Besides, filtration of DSP, 
DZ and SP aqueous solutions by columns filled in with a mixture of sand and micelle-clay complex showed complete removal of each drug at 
concentration higher than sand/activated-charcoal filled filters at flow rates of 2 mL min-1. 
Keywords: Dexamethasone sodium phosphate, Diazepam, Spironolactone, Activated sludge, Activated charcoal, Micelle – clay 
complex.
  
 
1. Introduction 
 
Persistent organic pollutants (such as polychlorinated 
biphenyls (PCBs), polycyclic aromatic hydrocarbons (PAHs)) 
have for many years been investigated regarding their 
influence on the environment [1]-[2], and have high acute 
toxicity, tendencies to undergo bioaccumulation and 
biomagnifications. They also have a high resistance against 
degradation and long half-life in the environment. 
Nowadays another concern is arising due to pharmaceuticals 
or their metabolites found in environmental samples. The 
presence of pharmaceutical residues in environmental bodies 
has increased the probability of toxicity risks for animals and 
humans in the last years [3]-[5]. It has been reported that the 
aquatic environment can become polluted with 
pharmaceutically active compounds (drugs) at low 
concentration because of the extensive consumption of 
pharmaceuticals in developed countries [6]-[7]. 
Persistence to biochemical degradation and polar structure, are 
indicated as mainly responsible for the incomplete removal of 
pharmaceuticals during conventional wastewater treatment 
plant [8]-[9] with efficiencies ranging between 60% and 90% 
for a variety of polar compounds [10]-[13]. To evaluate the 
efficiency of different traditional and innovative tools for the 
elimination of pharmaceutical residues, a series of water 
purification experiments were performing by using the WWTP 
installed at the Al-Quds University in Palestine as indicated in 
Figure 1 (appendix A), which includes sequential units as 
activated sludge (AS), ultra-filtration (UF), granular activated 
charcoal (GAC) and reverse osmosis (RO)[14]. 
Problems arising from the management of such a plant can be 
referred to the capability of the AS unit to favor the bio-
degradation of organic pollutants as well as the fouling 
phenomenon affecting membrane units, which must be often 
replaced with high costs. 
The present work reporting about the efficiency of advanced 
wastewater treatment technologies adopted in the Al-Quds 
plant for the removal of dexamethasone sodium phosphate 
(DSP), diazepam and spironolactone which were used as 
model pharmaceutical compounds due to its high solubility in 
water and large consumption in many Countries.  
Aiming at the assessment of bacterial culture, which normally 
develops in the AS unit of Al-Quds WWTP, the stability of 
DSP, DZ and SP in pure water as well as in the activated 
sludge collected from the plant were investigated and it’s 
degradation products were identified. 
Finally, in order to check for different tools to be used instead 
of ultra-filtration membranes, the effectiveness of micelle-clay 
(MC) filter for removing DSP, DZ and SP were ascertained 
and compared to a filter filled with granular activated 
charcoal. Besides, the adsorption equilibrium parameters and 
the adsorption Langmuir coefficients were determined using 
both micelle-clay and fine powder activated charcoal (FAC) as 
adsorbent materials. 
Dexamethasone sodium phosphate, 9-fluoro-11β,17-
dihydroxy-16α-methyl-21-(phosphonooxy) pregna-1,4-diene-
3,20-dione disodium salt (structure 1 in Figure 2, appendix A), 
a synthetic adrenocortical steroid, is a white or slightly yellow, 
crystalline powder. It is highly soluble in water and is 
exceedingly hygroscopic. It is widely used to treat 
inflammation, allergy and diseases related to adrenal cortex 
insufficiency. DSP is also known to reduce neointimal 
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hyperplasia in arteries [15]. This drug is one of the most 
potent corticosteroids with anti- inflammatory and 
immunosuppressive properties [15]-[16]. It is used for coating 
drug- eluting stents for local drug delivery to prevent 
restenosis [17]-[19] and is 5-14 times more potent than 
prednisolone and 25-75 times more potent than cortisone and 
hydrocortisone [20]. The corticosteroids cause alterations in 
metabolism of fats, proteins and carbohydrates, and affect a 
range of organs in the body including the heart, muscle and 
kidneys. Blood chemistry may change and there is decreased 
activity and shrinkage of the thymus gland, adrenal glands, 
spleen and lymph nodes. The liver becomes enlarged, thyroid 
activity decreases, and mineral is drawn away from bone. 
Muscle wasting occurs, and the immune system is adversely 
affected causing the person to be more susceptible to 
infections, especially of the eye [15]-[19]. DSP is one of the 
most water soluble of the adrenocorticoseroidal agents. It is 
therefore suitable for intravenous use and particularly for 
ophthalmic formulations [21]. 
Another important class of pharmaceuticals, which has 
received recent consideration, is known as benzodiazepines 
(structure 3, Figure 3, appendix A). One of the most 
commonly used medicine among the members of the 
benzodiazepines is diazepam (structure 4, Figure 3, appendix 
A) (7-chloro-l-methyl-5-phenyl-1,4-benzodiazepin-2-one). It is 
a long acting benzodiazepine with anticonvulsant, anxiolytic, 
sedative, and muscle relaxant properties [22]. It is used for the 
treatment of acute management of all types of seizures in both 
adults and children [23]. Diazepam is administered by oral, 
intravenous, or rectal route [24]. 
Most pharmaceuticals undergo biotransformation in the human 
body, resulting in a release of significant amounts of a variety 
of metabolites into the aquatic environment, which can be 
further transformed during the sewage treatment processes 
(biotic degradation) [25]. Pharmaceuticals may also be 
chemically degraded by abiotic processes such as hydrolysis, 
oxidation and photolysis. The degradation products can be 
also of concern because of their possible toxicity, which can 
sometimes be higher than that of the corresponding parent 
compound [26]-[27]. 
Diazepam (4) is metabolized in human liver via cytochrome 
P450 enzymes pathway. It has an elimination half-life of 20-
100 h, and produces several pharmacologically active 
metabolites; the main active metabolites are obtained through 
desmethylation mechanism (5, nordiazepam, t½ = 36-100 h), 
temazepam (6, t½ = 8-22 h), and oxazepam (7, t½ = 4-15 h) as 
shown in figure 4, appendix A [28]. Diazepam and their 
metabolites are conjugated with glucuronide and are excreted 
primarily in the urine. From human metabolism studies it has 
been shown that 30% of diazepam dose administered to 
patients is exerted without any change, 12% as nordiazepam 
(5), 15% as temazepam (6) and 32% as oxazepam (7);11% of 
the dose remaining is still unidentified [29]. The diazepam 
metabolism is mediated by a number of cyctochrome P450 
enzymes and proceeds by both N-dealkylation and C3-
hydroxylation reactions [28]-[30]. 
Among these pharmaceuticals Spironolactone (SP), a 
synthetic, yellowish, crystalline solid, is considered as one of 
the most widespread [31]. SP (8), (7α-acetylthio-3-oxo-17α-
pregn-4-ene-21,17-carbolactone) [31] (Figure 5, appendix A), 
is a competitive aldosterone antagonist, which belongs to the 
steroid class of chemical compounds. SP is practically 
insoluble in water, soluble in alcohol, and freely soluble in 
benzene and in chloroform. SP is a potassium-sparing diuretic 
(water pill) that prevents body from absorbing too much salt 
and keeps potassium levels from getting too low. It has been 
widely used to treat inflammation, allergy and diseases related 
to adrenal cortex insufficiency. Spironolactone is also known 
to diagnose or treat a condition in which the body has too 
much aldosterone (hormone produced by adrenal glands to 
help regulate the salt and water balance in human body) [31]. 
SP is also used to reduce edema caused by heart, liver or 
kidney problems, hypertension, and hyper aldosteronism. 
Common side effects of SP include skin rash, headache, 
dizziness, and stomach pain [31]. Serious side effects of SP 
include hyperkalemia, altered heart beats, confusion, tremors, 
decreased or no urine output, shallow breathing, muscle pain 
or weakness, and numbness [31]. 
SP is rapidly and extensively metabolized in human to (7α-
thiomethylspirolactone) and Canrenone [32]. Sulfur-
containing products are the predominant metabolites and are 
thought to be primarily responsible, together with spironol, for 
the therapeutic effects of the drug [31]. It is extensively used 
in medicine, though until recently it was considered only as 
potassium-sparing diuretic and anti- hypertensive drug. It may 
also reverse aldosterone-induced cardiac fibrosis and improve 
morbidity and survival of patients with congestive heart failure 
[33]-[34]. 
Furthermore, it is used in neonates, infants and children with 
congestive heart failure secondary to congenital heart disease 
[35]. As with many other frequently used drugs, SP is 
available only as tablets, rather than in liquid dosage form 
suitable for pediatrics use. Over the last 25 years, many 
extemporaneously prepared SP containing oral liquid 
formulations have been reported in the literature, as well as 
their physical and chemical stability [36]-[42]. 
Pramar et al. [43] observed that the decomposition of SP 
consists of a series reaction (Spironolactone, Canrenone and 
unidentified products) or a combination of series and side 
reactions since some of the SP may also directly change into 
some unidentified products, which is probably the reason for 
the absence of the Canrenone in the chromatograms. 
Moreover, it has also been suggested that in acidic medium the 
lactone would hydrolyze reversibly [43]. Canrenone (CR) (9), 
(10,13-dimethylspiro [2 ,8, 9, 11, 12,14,15,16-octahydro-1H-
cyclopenta [α] phenan-threne-17,5'-oxolane]-2',3-dione) 
(Figure 6, appendix A), a cardiovascular drug, a sort of 
steroid, is spironolactone’s major metabolite and has been 
widely used as a nonselective aldosterone receptor antagonist 
clinically to treat heart failure, high blood pressure, edema, 
liver ascites, and other cardiovascular diseases [44]. 
Canrenone, (9), (C22H28O3) a pale yellow to pale green solid 
used as aldosterone antagonist. The production of (11-α-
hydroxy-canrenone) (10) by the 11-α-hydroxylation reaction 
can be conducted by chemical synthesis or microbial 
transformation (Figure 7, appendix A) [31]. 
The 7α-acetylthio substituent is removed completely from 
80% of the administered dose yielding Canrenone as the 
principal non-conjugated metabolite in plasma. Canrenone is 
active as a Mineral corticoidant agonist in animals, and has 
been proposed as the principal pharmacologically active agent 
after administration of SP to man. Potassium canrenoate (11), 
the potassium salt of asteroid acid, is also active as an 
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aldosterone antagonist and has found clinical use in certain 
areas of the world. After administration of this drug to human 
both Canrenoate (12) (Figure 8, appendix A) and Canrenone 
(9) are found in plasma. Evidence from in vitro studies 
indicates that Canrenoate has a low affinity for aldosterone 
binding proteins, and is unlikely to contribute significantly to 
pharmacological activity [45]. In vitro studies have also 
suggested that Canrenone is the principal active metabolite of 
potassium canrenoate [45]. 
The micelle-clay composite, which was used in this study, is 
positively charged, has large surface area and includes large 
hydrophobic domains [46]. Micelle-clay composites have 
already been proven useful in the removal of about 20 neutral 
and anionic pollutants [46]-[50]. 
  
      2. Experimental 
2.1 Materials and Equipments 
2.1.1 Materials. 
All chemicals were of analytical grade. The clay used was 
Wyoming Na- montmorillonite SWY-2 clay; obtained from 
the Source Clays Registry (Clay Mineral Society, 
Colombia, MO). Quartz sand (grain size 0.8—1.2 mm) was 
obtained from Negev industrial minerals (Israel). 
Octadecyltrimethylammonium (ODTMA) bromide was 
obtained from Sigma Aldrich. Pure DSP and its hydrolysis 
product dexamethasone, Diazepam and Spironolactone 
were obtained from Birzeit Pharmaceutical Company 
(Palestine) with 99% purity, and all were used as received. 
Fine powder activated charcoal (FAC) with particle size ≤ 
60.0 µm, and granular activated charcoal (GAC) with 
particle size ≤ 700.0 µm were obtained from Sigma (Sigma 
Chemical Company, USA). The powder was used for batch 
adsorption experiments while the granules were used in 
column experiments. Magnesium sulfate anhydrous, 
potassium dihydrogen phosphate as well as methanol and 
water for analysis (HPLC grade) were purchased from 
Sigma Aldrich (Munich, Germany). High purity diethyl 
ether (> 99%) was purchased from Biolab (Israel). For 
sample enrichment and purification SPE 1g C-18 6 mL 
disposable cartridges (Waters, Milford, MA, USA) were 
used. 
 
2.1.2 Equipment. 
Samples were shaken using Big Bill, (Banstaed/ 
Themolyne, USA).  The disappearance of DSP and its 
hydrolysis product were determined by using a high 
pressure liquid chromatography system model 2695 HPLC 
from Waters (Israel), equipped with a Waters 2996 
Photodiode array. Data acquisition and control were carried 
out using Empower ™ software (Waters, Israel). Analytes 
were separated on a 4.6 mm x150 mm C18 XBridge® 
column (5 μm particle size) used in conjunction with a 4.6 
mm, 20 μm, XBridge® C18 guard column. 
 
HPLC conditions : mixture of 0.01M KH2PO4: methanol 
(1:1; v/v) as mobile phase for DSP; acetonitrile: water (1:1; 
v/v) for DZ and Acetonitrile (40:60; v/v) as mobile phase 
for DZ, flow rate of 1.5 mL min
-1
; UV detection for DSP 
and SP at a wavelength of 254 nm and 230 nm for DZ. 
Acrodisc® syringe filters with GHP membrane (hydrophilic 
polypropylene 0.45μm porosity) from Waters were always 
used for all analytical filtration requirements. 
 
The identification of drugs degradation products were 
performed using a liquid chromatography system coupled to 
a hybrid linear quadrupole ion trap (LTQ) – Fourier-
transform ion cyclotron resonance (FT-ICR) mass 
spectrometer (Thermo Fisher Scientific, Bremen, 
Germany). 
The advanced wastewater treatment plant employed in this 
study is located at Al-Quds University-Palestine and was 
described in detail elsewhere [50]-[51]. Normally, the 
effluent from this plant is recycled for the irrigation of 
plants cropped in the field of university Campus. 
2.2 Methods 
2.2.1 Characterization of wastewater used. 
The wastewater was characterized before the experiments 
according to American Public Health Association 
procedures [52],[27] by performing measurements listed in 
Table 1, appendix B. 
 
2.2.2 Efficiency of WWTP for DSP, dexamethasone, DZ 
and SP removal. 
The efficiency of different treatment units was ascertained 
by spiking separately the secondary effluent with 1.0 mg L
-1
 
of either DSP or its hydrolysis product dexamethasone, DZ 
and SP in the activated sludge reservoir (1000 L). Samples 
were collected from different locations of the WWTP as 
depicted in figure 1, appendix A. Before analysis of DSP, 
1mg of KH2PO4 was added to 100 mL of sample to 
stabilize pH, the acidic form of DSP, and the ionic strength 
of the solution. SPE-C18 disposable cartridges were used to 
pre-concentrate 10 mL of each sample by adsorption of 
analytes. A part (20 µL) of the methanolic solution eluted 
from SPE cartridge was injected into the HPLC, and 
analyzed using the same conditions for the determination of 
DSP, dexamethasone, DZ and SP. Recovery tests were 
performed using triplicate solutions of all substances, and 
values ranging from 98% to 102% were obtained. 
 
2.2.3 Stability of DSP, DZ and SP. 
Prior to perform any other experiment, stability study of 
DSP , DZ and SP were performed using 100 mg L
-1
 
solutions in pure water, or activated sludge taken from the 
WWTP installed at Al-Quds University to ascertain if 
hydrolysis or bio-degradation reactions had taken place 
before the filtration stages. For this reason, Samples at 
specific time intervals were collected from the stability 
solutions (maintained under continuous orbital shaking), 
filtered, and analyzed by HPLC. The degradation by-
products of DSP, DZ and SP were investigated using liquid 
chromatography/Fourier-transform ion cyclotron 
resonance/mass spectrometry (LC/FT-ICR/MS). 
 
2.2.4 Micelle-clay complex preparation. 
The ODMTA micelle-clay complex was prepared by 
mixing a smectitic clay- mineral (montmorillonite) with the 
cationic surfactant octadecyltrimethylammonium (as 
bromide salt) with a critical micelle concentration (CMC) 
value of 0.3 mM as described previously [50]. The obtained 
complex by virtue of its positive charge and hydrophobic 
region is capable of efficiently binding neutral and 
negatively charged organic molecules [47]-[51]. 
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2.2.5 Batch adsorption experiments. 
Batch adsorption experiments were carried out on DSP, DZ 
and SP at different concentrations. Experiments were 
performed in 250 mL Erlenmeyer flasks containing 200 mg 
of either micelle-clay complex or fine powder activated 
charcoal (FAC); 100 mL of each drug solutions having 
known initial concentration were then introduced into each 
flask. The flasks were shaken in an oscillating shaker for 
three hours at room temperature, and then the content of 
each flask was centrifuged (10,000 g) for 5 min and filtered 
using 0.45 μm filters. The equilibrium concentrations of 
DSP, DZ and SP were then obtained by HPLC, using the 
conditions reported above. The retention time of DSP was 6 
min, 4.2 min for DZ and 6.9 min for SP. 
 
2.2.6 Column filtration experiments. 
Column filtering experiments were performed using 50/1 
(w/w) mixtures of quartz sand and either ODTMA-clay 
complex, or granular activated charcoal (GAC), 20 cm 
layered in borosilicate columns of 25 cm length and 5 cm 
diameter. Each column contained 13 g of complex, or 
GAC. The bottom of the column was covered with 3 cm 
layer of quartz sand. Quartz sand was thoroughly washed by 
distilled water and dried at 105 °C for 24h before its use. 
Solutions in pure water (1 L each) containing different 
DSP, DZ and SP concentrations (0.01, 1, 10, and 100 mg L
-
1
) were passed through either micelle-clay or GAC columns 
(one column for each solution). In all cases the flow rate 
was 2.0 mL min
-1
. Eluted fractions were collected in all 
column experiments and analyzed. 
All experiments reported in sections 2.2.1- 2.2.6 were 
performed in three replicates and average values and 
standard deviations were calculated 
 
3. Results and discussion 
3.1 Calibration curves 
Linearity of the proposed analytical method was verified by 
analyzing standard solutions in the range of 0.1 - 100 mg L
-
1
 for both DSP and its hydrolysis product, for DZ and SP in 
pure water. The calibration curves were obtained with a 
determination coefficient R
2 
between 0.9996- 0.9998, 
respectively. The repeatability of triplicate subsequent 
injections was ranging from 98.5% to 99.5%, depending on 
the sample concentration and type of analyte. The 
repeatability of morning/evening injections on the basis of 
6-hours elapsed time was ranging from 97.6% and 98.2%, 
and was also affected by the concentration and type of 
analyte. Correction coefficients were used for experimental 
samples. 
 
Calibration curves and repeatability trials were repeated 
preparing new calibration solutions by using wastewater 
taken from the activated sludge reservoir of Al-Quds 
WWTP. Results suffered of a major inaccuracy due to the 
variability of recovery percentages. Anyway, the 
determination coefficients of calibration curves were 
0.9985 for DSP, 0.9989 for dexamethasone, 0.9996 for 
diazepam and 0.9999 for spironolactone. Repeatability 
normally was not reduced. The limit of detection, based on 
a signal/noise of 3, was 0.02 mg L
-1
 for DSP, 0.01 mg L
-1
 
for dexamethasone, 0.03 mgL
-1
 for both DZ and SP. The 
limit of quantification, based on a signal/noise of 10, was 
0.06 mg L
-1
 and 0.03 mg L
-1
 for DSP and its hydrolysis 
product, respectively, 0.08 mgL
-1 
and 0.05 mgL
-1
 for DZ 
and SP. 
3.2 Wastewater characteristics 
Table 2, appendix B summarizes chemical, physical and 
biological characteristics of wastewater sampled from the 
activated sludge reservoir of Al-Quds WWTP ( figure 1, 
appendix A). Table 2 shows that this wastewater contains 
high amounts of suspended solids and organic pollution 
load, the relatively high values of TSS and COD may be 
attributed to residues of chemicals in the wastewater from 
laboratories, which were not well removed by the 
sedimentation stage and secondary biological treatment. 
This table also reveals that the wastewater contained high 
amounts of suspended solids and large populations of 
bacteria, which are responsible of fouling phenomena 
affecting ultra-filtration and reverse osmosis membranes. 
Moreover, high values of electrical conductivity and total 
dissolved solids, are typical for municipal wastewaters, and 
should be reduced if WWTP effluents are re-used for crop 
irrigation purposes. 
 
Al-Quds activated sludge was found to contain 
Enterobacter and Pseudomonas species: Escherichia coli, 
Enterobacter sakazakii, Citrobacter freundii, Pseudomonas 
aeruginosa, Klebsiella  pneumonia, Enterobacter cloacae, 
Enterobacter amnigenus, Enterobacter aerogenes, 
Salmonella spp., and Serratia liquefaciens [54]. 
 
Further challenge will be the isolation of strains constituting 
the bacterial colonies, aiming at the identification of the 
more active strains capable of utilizing the pharmaceutical 
molecules as energy source. 
 
3.3 Efficiency of WWTP for DSP, dexamethasone, DZ 
and SP removal 
The efficiency of WWTP at Al-Quds University for the 
removal of DSP, dexamethasone, DZ and SP were studied. 
The activated sludge reservoir (site 1 in figure 1, appendix 
A) was separately spiked with either DSP or 
dexamethasone, DZ and SP at concentration of 1.0 mg L
-1
, 
which is an amount close to literature findings [55]- [56]. 
Samples were taken from different collecting sites of 
WWTP as described in section 2.2.2 and figure 1, appendix 
A. Analytical results of water effluent from the hollow fiber 
ultra-filtration membrane (UF-HF) indicated that DSP was 
about 63% removed at this stage, whereas about 95% of 
DSP was removed after passing the spiral wound (UF-SW) 
membrane (Table 3, appendix B). Besides, DSP was 
completely removed in the effluent from GAC filter. 
However, it should be outlined that the concentration of 
DSP (or dexamethasone) influent in the treatment units was 
diminishing along their sequence. This relationship 
reflected upon 100% removal by GAC filter, which influent 
water contained only 0.06 mg L
-1
 of DSP, or 0.07 mg L
-1
 of 
dexamethasone, on average, after the passage into the UF 
filters. 
 
Analytical results of water effluent from the hollow fiber 
ultra-filtration membrane (UF-HF) indicated that the 
diazepam removal at this stage was about 82.1%, whereas 
about 90.4% of the drug was cumulatively removed after 
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passing the spiral wound (UF-SW) membrane (Table 4, 
appendix B). 
Additionally, there was no complete removal of diazepam 
from the effluent exiting the GAC filter (93.7%); whereas, 
the RO unit showed 100% diazepam removal. It should be 
worth noting that the concentration of diazepam in the GAC 
effluent was 0.05mg L
-1
, whereas, after the passage into the 
UF filters the concentration in the GAG influent water was 
just a little bit higher (0.08 mg L
-1
). 
 
Finally, Analytical results of water effluent from the hollow 
fiber ultra-filtration membrane (UF-HF) indicated that SP 
was about 69.9% removed at this stage, whereas about 
92.8% of SP was removed after passing the spiral wound 
(UF-SW) membrane (Table 5, appendix B). Besides, SP 
was completely removed in the effluent from GAC filter. 
However, it should be outlined that the concentrations of 
SP influent in the treatment units were diminishing along 
their sequence. This relationship reflected upon 100% 
removal by GAC filter, whose influent water contained only 
0.06 mg L
-1
 of SP, on average, after the passage through the 
UF filters. 
 
That finding made unnecessary the use of reverse osmosis 
for any further purification. Nevertheless, the advanced 
technology adopted in the WWTP of Al-Quds University 
did not overcome a problem common to all plants: the 
production of brine, in which a large portion of the 
contaminants ends up being concentrated there. For this 
reason different methods of water filtration and purification 
should be experimented. 
 
3.4 Stability of DSP, DZ and SP in pure water and in 
sludge 
Literature survey on the stability of DSP suggests that the 
drug undergoes degradation in aqueous solutions buffered 
at various pH values, temperature, light exposure and 
oxidative conditions [57]. Furthermore, DSP cleaves into 
four major degradation products. They were identified as 
dexamethasone-21-oic acid, 17-oxodexamethasone, 6ß-
hydroxy dexamethasone, and 16, 17-unsaturated 
dexamethasone [58]. 
Figure 9, appendix A illustrates the HPLC chromatogram of 
DSP after two weeks of incubation in pure water at room 
temperature (C(0) = 100 mg L
-1
). The peak at 6-minutes 
retention time is characteristic of the acidic form of DSP 
and the peak at 10.3-minutes can be attributed to its 
hydrolysis product dexamethasone.  
The kinetic data of DSP hydrolysis in pure water are plotted 
in figure 10, appendix A (plot a) as natural logarithm of 
DSP concentration vs. time (days). The determination 
coefficient R
2
 of the first order hydrolysis reaction was 
0.9981, and the kinetic constant was 3.25 10
-7
 s
-1
. 
Similarly, kinetic study on the stability of DSP was 
conducted in the activated sludge at room temperature. The 
determination coefficient R
2
 in this case was 0.9987 (Figure 
10, plot b, appendix A), and the kinetic constant was 3.80 
10
-6
 s
-1
. The degradation half-life was diminished from 24.7 
days in pure water to 2.1 days in the activated sludge where 
the concentration of the mother molecule was found at level 
of 1 mg L
-1
 after two weeks of incubation. The degradation 
rate in the sludge medium was about 12-fold faster than in 
pure water. The accelerated degradation can be attributed to 
bioactivity of the activated sludge. 
 
The kinetic parameters of diazepam hydrolysis in pure 
water (100 mg L
-1
) are illustrated in figure 11, appendix A 
as natural logarithm of diazepam concentration vs. time 
(days). The determination coefficient R
2
 of the first order 
hydrolysis reaction was 0.9981, and the rate constant was 
9.08 x 10
-8
 s
-1
 at pH 7.3. 
Similarly, kinetics of diazepam in Al-Quds activated sludge 
at room temperature was studied starting from the same 
concentration used in pure water. The determination 
coefficient R
2
 in this case was 0.9987 (Figure 11, appendix 
A), and the rate constant was 2.60 x 10
-7
 s
-1
.The 
degradation half-life was diminished from 88.3 days in pure 
water to 30.4 days in the activated sludge, where the 
concentration of diazepam was found at a concentration of 
14.4 mg L
-1
 after 60 days of incubation. The degradation 
rate in the sludge medium was about 3-fold faster than in 
pure water. The accelerated degradation can be attributed to 
the bioactivity of bacteria populations present in the 
activated sludge. 
 
Kinetic studies on SP stability in pure water and sludge 
conditions have been undertaken, starting from an initial 
solution of 100 mg L
-1
. The results showed that SP was 
unstable in both distilled water and Al-Quds University 
activated sludge, being susceptible to water hydrolysis and 
bacterial degradation. In both cases the degradation 
followed a first order rate with values of the rate constants 
being 7.4 × 10
-7
 s
-1
 and 3.6 × 10
-5
 s
-1
, in pure water and in 
activated sludge, respectively. 
 
The degradation half-life was diminished from 10.7 days in 
pure water to 0.22 days in the activated sludge where the 
concentration of the parent molecule was found at a level of 
4.6 mg L
-1
 after one day of incubation.  
 
Monitoring the derivative substances arisen from the 
degradation of DSP in the activated sludge evidenced that 
the first degradation product, dexamethasone, underwent 
further degradation to other by-products as identified by 
mass spectrometrical analysis. Extracted ion chromatogram 
(XIC) of the 14-days biodegraded sample is shown in figure 
12, appendix A. The benefit of using very selective 
extracted ion chromatograms by FTICR/MS, generated 
with a tight mass-to-charge ratio window of ±0.0010 units 
around each selected protonated molecule (i.e., [M+H]
+
 
±1.0 mDa), greatly reduced the signal complexity of the 
total ion current trace (data not shown) allowing to 
completely characterize all degradation products. 
 
In addition to dexamethasone, which was formed from 
hydrolysis of dexamethasone sodium phosphate, seven 
major biodegradation products were identified arising from 
dexamethasone biodegradation at retention times 8.53(13), 
10.23(14), 9.68(15), 10.11(16), 8.59(17), 8.59(18) and 
10.48(19) minutes. Based on the accurate m/z values (Table 
S1, in Supplementary material) and relevant literature [58], 
we propose the following structures for all degradation 
products evolved (Figure 13, appendix A): 
C20H25FO3 [17-oxodexamethasone] (13), 
C22H29FO6 [6’-hydroxy dexamethasone] (14), 
C20H27FO3 [testosterone] (15), 
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C22H28O6 [3',4'-dihydroxy-10,13-dimethylspiro [1,2,6, 7, 
8,9,12,14,15,16-deca hydro cyclopenta [α] phenanthrene-
17,5'-oxolane]-2',3,11-trione] (16), 
C20H22O2 [(8S,13S,14S,17S)-13-methyl-3-oxo-2,6,7, 8,14, 
15,16,17-octahydro-1H-cyclopenta [α] phenanthren-17-yl] 
(17), C20H24O3 [(8S,13S,14S,17R)-17-ethynyl-17-hydroxy-
13-methyl-1,2,6,7,8,14,15, 16-octahydrocyclopenta [α] 
phenanthren-3-one] (18), C22H31O6F [6-Fluoro-
11,14,17,21-tetrahydroxy-16-methylpregn-4-ene-3,20-dione 
(19). 
Figure 14, appendix A describes the suggested pathway by 
which dexamethasone degrades to metabolites (14) and 
(19). The hydroxyl group can attack two different positions 
on the dexamethasone moiety. Figure 15, appendix A 
illustrates the proposed pathways for the degradation of 
(14) to the other degradation products (13, 16, 17 and 18). 
 
The FTICR IRMPD (infrared multiphoton dissociation) 
MS/MS spectrum, reported in figure S1 (Supplementary 
material), shows that compound (18) gives a molecular 
peak at m/z 313 and three fragments with m/z 295 [M-
H2O+H]
+
, 277 [M-2H2O+H]
+
, and 267 [M-H2O-CO+H]
+
, 
due to the loss of H2O and CO. In figure 15, Appendix A, 
the first way (A-B) leads from compound (14) to compound 
(13) by the loss of H2O, formaldehyde and CO moieties, 
then to compound (18) through the loss of HF. The second 
way (C-D) leads from compound (14) to compound (16) by 
the loss of HF molecule, and successively to compound 
(18) with the loss of water, formaldehyde and CO groups. 
 
At our knowledge no papers have been published on 
biodegradation of DSP or dexamethasone in wastewater. 
However, there are some in vitro and in vivo studies in rat 
and human livers on DSP metabolism to 17-
oxodexamethasone and 6-hydroxy dexamethasone, which 
are two of main derivative substances we report in figure 13 
as number (13) and (14), and side chain cleaved metabolites 
[58] having a structure different from derivatives identified 
in our work. 
 
Monitoring the substances arising from the degradation of 
SP in the activated sludge indicated that SP underwent 
degradation to two by-products, as identified by mass 
spectrometrical analysis. Extracted ion chromatogram 
(XIC) of the 16-days biodegraded sample is shown in figure 
16, appendix A. The benefit of using very selective 
extracted ion chromatograms by FTICR/MS, generated 
with a tight mass-to-charge ratio window of ±0.0010 units 
around each selected protonated molecule (i.e., [M+H]
+
 
±1.0 mDa), greatly reduced the signal complexity of the 
total ion current trace (data not shown) allowing to 
completely characterize all degradation products. 
 
Degradation products of SP in wastewater solution were 
identified through LC/MS analysis, which showed that SP 
can degrade to two metabolites, Canrenone (C22H28O3) (9) 
(Figure 6, appendix A) with high percent and to other 
metabolites, e.g., Canrenoic acid (20) (Figure 17, Appendix 
A) which has the chemical formula (C22H30O4) with less 
amount; the analysis showed that SP was still present in 
solution but at very low concentration. All metabolites were 
identified with an error lower than 2 ppm. 
 
There is no predominant metabolite containing sulfur which 
is thought to be primarily responsible together with 
spironolactone for the therapeutic effects of the drug [31]. 
LCMS analysis results agree with the conclusions of Pramar 
et al.[38] who described Spironolactone decomposition to 
Canrenone by a series of reaction [Spironolactone → 
Canrenone→ unknown products]. Spironolactone is 
extensively metabolized in humans, and ≈79% of the 
spironolactone oral dose is converted to canrenone, its 
major biologically active metabolite [38]. Canrenone 
undergoes hydrolysis of its γ-lactone ring to canrenoic acid 
(CA), which is water soluble. Thus, after equilibrium, 
similar plasma concentrations of CA and canrenone are 
reached [45]. LCMS analysis showed no presence of 
metabolites containing potassium or sodium; this disagrees 
with other evidence from invitro studies,[45] which 
suggested that Canrenone is the principal active metabolite 
of potassium canrenoate. 
 
3.5 Adsorption isotherms 
The adsorption of DSP, DZ and SP at several initial 
concentrations on micelle-clay complex and activated 
charcoal were investigated. Equilibrium relationships 
between adsorbent and adsorbate can be described by 
Langmuir adsorption isotherm [50], represented by 
equation (1): 
Ce/Qe=1/(k.Qmax)+Ce/Qmax                                               (1) 
where Ce (mg L
-1
) is the equilibrium concentration of the 
drug in the solution, Qe (mg g
-1
) is the equilibrium mass of 
adsorbed drug per gram of complex or activated charcoal, k 
(L mg
-1
) is the Langmuir binding constant, and Qmax (mg g
-
1
) is the maximum mass of drug removed per gram of 
complex. 
 
DSP Data fitted well the Langmuir equation giving R
2
 = 
0.9953 for activated charcoal and 0.9997 for the micelle-
clay (Figure 18, appendix A). The calculated Langmuir 
constants k and Qmax are presented in table 6, Appendix B. 
The values of k and Qmax parameters for the adsorption 
isotherm obtained using micelle-clay complex were larger 
than those concerning activated charcoal, suggesting the 
former as the best adsorbent for DSP removal. In particular, 
the Langmuir binding constant <k> for micelle-clay 
complex was about 15 fold greater compared to the 
activated charcoal, and the value of Qmax was nearly 6 fold 
higher for the former. 
 
Diazepam data fitted well the Langmuir equation giving R
2
 
= 0.9945 for activated charcoal, and 0.9970 for the micelle-
clay (Table 7, appendix B). The calculated Langmuir 
constants k and Qmax are presented in Table 7, Appendix B. 
The values of k and Qmax parameters for the adsorption 
isotherm obtained using micelle-clay complex were larger 
than activated charcoal, suggesting the former to be a more 
efficient adsorbent for diazepam removal. In particular, the 
Langmuir binding constant <k> for micelle-clay complex 
was about 1.4 fold greater than activated charcoal, and the 
value of Qmax was nearly 1.1 fold higher for the former.  
 
The data fitted well the Langmuir equation for SP giving R
2
 
= 0.964 for activated charcoal and 0.935 for the micelle-
clay. The calculated Langmuir constants k and Qmax are 
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presented in Table 8, appendix B. The values of k and Qmax 
parameters for the adsorption isotherm obtained using the 
micelle-clay complex were 1.2- and 1.7- fold larger than the 
corresponding values deduced for activated charcoal. The 
analysis of the Langmuir equation yields that a deduction of 
an overestimate for the value of Qmax would yield an 
underestimate in the value of k and vice versa. The 
presentation of the Langmuir equation in another form as in 
[47] emphasizes the fact that the quantity which governs the 
adsorption is the product k* Qmax. Hence we added in Table 
8, appendix B, this quantity, whose values are 58.7 and 
28.6 Lg
-1
, for the adsorption of SP by the micelle-clay, or 
activated charcoal, respectively, which emphasizes the 
former as the better adsorbent for SP removal.  
 
3.6 Filtration results 
DSP, DZ and SP solutions were passed separately through 
filters which included the micelle-clay complex or activated 
charcoal mixed with excess sand at 1:50 ratios (w/w). 
Results (Table 9, appendix B) indicate a significant 
advantage of the micelle-clay filter in removing DSP 
compared to the drug amount removed by activated 
charcoal. The efficiency of filter filled with activated 
charcoal and sand was acceptable only for the lowest DSP 
concentration while the micelle clay system was able to 
retain the drug also at the higher concentration 
experimented. This finding was not surprising, since 
parameters obtained for adsorption isotherms have clearly 
shown that the micelle-clay complex was more efficient 
than activated charcoal in adsorbing DSP from water. 
 
Diazepam solutions were passed through filters which 
included the micelle-clay complex or activated charcoal 
mixed with excess sand at 1:50 ratio (w/w). The results 
shown in Table 10, appendix B indicate a significant 
advantage of the micelle-clay filter in removing diazepam 
compared to the amount removed by the activated charcoal. 
The efficiency of filter filled with activated charcoal and 
sand was adequate only for the lowest diazepam 
concentration, while the micelle clay system was able to 
remove the drug also at the higher concentration 
experimented. This result is not surprising, since the 
parameters obtained for adsorption isotherms of the two 
adsorbents clearly showed that the micelle-clay complex 
was more efficient than activated charcoal in adsorbing and 
removing diazepam from water. 
 
The results in Table 11 (Appendix B) demonstrate removal 
of SP by filtration of 1 L of its several solutions (100, 10, 
1.0, 0.01 mg L
-1
) through a filter which included mixtures 
of micelle-clay or activated charcoal with excess sand. 
Complete removal was observed for SP concentrations of 
10 mg L
-1
 or less by both filters. In the case of the higher 
concentration of 100 mg L
-1
 the emerging concentration of 
SP through the activated charcoal filter was almost two-fold 
larger than through the micelle-clay filter. This result is in 
accord with the results of adsorption in suspension, 
indicating the higher efficiency of the micelle-clay complex 
to remove this pharmaceutical from water. 
 
Previously reported experiments demonstrated the poor 
capability of activated carbon filters towards removing of 
anionic and certain neutral pollutants [47-49]. 
Polubesova et al. [47] found very efficient removal of three 
anionic pollutants (imazaquin, sulfentrazone, sulfosulfuron) 
and 4 neutral pollutants (alachlor, acetochlor, chlorotoluron 
and bromacil) by micelle –clay complexes in aqueous 
dispersions. In another study [48] column ﬁlters filled with 
a mixture of quartz sand and micelle–clay complex 
provided very efficient result for the retention of 
tetracycline and sulfonamide pharmaceuticals from 
wastewater. 
Zadaka et al. [49] tested column filters with either a mixture 
of quartz sand and organic micelle – montmorillonite or 
zeolite; both filters were capable to well remove ethylene 
di-bromide, anionic pollutants as sulfosulfuron, imazaquin 
and sulfentrazone, and neutral compounds as bromacil and 
chlorotoluron from aqueous environments; in contrast a 
filter filled with the same weight of activated carbon and 
sand removed only partially these pollutants. 
In a recent paper, Karaman et al. [50] showed that micelle-
clay filters are more efficient towards removal of diclofenac 
potassium from wastewater than activated carbon. 
Moreover, Khamis et al. [27] concluded that the 
incorporation of micelle-clay filters in sewage treatment 
systems with loose tertiary capability can be a promising 
technology. More recently, Khalaf et al. [51] suggested that 
the integration of clay-micelle complex ﬁlters in existing 
WWTPs may be helpful for improving removal efficiency 
of recalcitrant residues of non steroid anti inflammatory 
drugs (NSAIDs). 
 
It can be argued that in addition to DSP, DZ and SP 
residues wastewater usually includes other recalcitrant 
organic pollutants. In such cases GAC filters can be used as 
first stage tertiary process to remove the majority of neutral 
pollutants, and additional micelle-clay filters can be 
adopted as second stage to eliminate anionic pollutants, and 
neutral compounds not retained by GAC filters. 
 
4. Conclusions 
The kinetic study revealed that DSP and SP were unstable 
in pure water and in sludge. The degradation products were 
identified by LC-MS and LC/MS/MS techniques, and those 
occurred in the sewage sludge were found to include not 
only the already known metabolites 17-oxodexamethasone 
and 6’-hydroxy dexamethasone for DSP and Canrenone as 
known metabolites for SP , but also many others derivatives 
not previously investigated. 
 
Diazepam was found to undergo not-complete degradation 
both in water and sludge. Hence, further removal of this 
pharmaceutical from WWTP effluents can be a required 
issue. The WWTP of Al-Quds University showed that the 
advanced treatment technologies installed were effective for 
the complete removing of few quantities of both DSP and 
its hydrolysis product and also SP from 1 mg L
-1
 spiked 
wastewater. 
 
The filtration performed using the mixture sand/micelle-
clay complex was able to retain very high concentrations of 
DSP, DZ and SP from aqueous solutions. The large 
effectiveness and removal capacity of the micelle-clay 
complex are due to the high adsorption affinity towards the 
anionic DSP by the relatively large number of positively 
charged and hydrophobic sites of the micelle-clay complex 
based on ODTMA. The results indicate that integration of 
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micelle clay complex is very promising in achieving 
complete elimination of this drug from WWTP effluents. 
 
References 
[1] K. Breivik, A. Sweetman, J. Pacyna, and K. Jones, 
―Towards a global historical emission inventory for selected 
PCB congeners - a mass balance approach. Global production 
and consumption,‖ Science of the Total Environment, 290(1-
3), pp. 181-198, 2002. 
[2] Commission Regulation (EC) No 1881/2006, Maximum 
levels for certain contaminants in foodstuffs,OJEU., Dec. 
20th, 2006, L 364/5. 
[3] B. Hailing-Sorensen, S.N. Nielsen, P.F. Lanzky, F. 
Ingerslev, H.C.H. Lutzhoft, and S.E. Jorgensen, ―Occurrence, 
fate and effects of pharmaceutical substances  
in the environment - A Review,‖ Chemosphere, 36, pp. 357-
394, 1998. 
[4] C. Daughton, T. Jones-Lepp, eds., Pharmaceuticals and 
personal care products in the environment: scientific and 
regulatory issues, American Chemical Society, Washington 
DC, 2001. 
[5] O.A. Jones, J.N. Lester, and N. Voulvoulis, 
―Pharmaceuticals: a threat to drinking water,‖ Trends 
Biotechnology, 23, pp.163-167, 2005. 
[6] T.A. Ternes, ―Occurrence of drugs in German sewage 
treatment plants and rivers,‖ Water Research, 32(1998) 3245- 
3260. 
[7] C.G. Daughton, T.A. Ternes, ―Pharmaceuticals and 
personal care products in the environment: agents of subtle 
change,‖ Environmental Health Perspectives,107, pp. 907- 
938, 1999. 
[8] T. Heberer, ―Occurrence, fate, and removal of 
pharmaceutical residues in the aquatic environment; a 
review,‖ Toxicology Letter, 131, pp.5-17, 2002. 
[9] T.A. Ternes, ―Occurrence of drugs in German sewage 
treatment plants and rivers,‖ Water Research, 32 , pp. 3245-
60, 1998. 
[10] O.A.H. Jones, N. Voulvoulis, J.N. Lester, ―Human 
pharmaceuticals in wastewater treatment processes,‖ Critical 
Reviews in Environmental Science and Technology, 35, pp. 
401-427, 2005. 
[11] R. Hirsch, T.A. Ternes, K. Haberer, K.L. Kratz, 
―Determination of beta blockers and b-sympathomimetics in 
the aquatic environment,‖ VomWasser, 87, pp. 263-74, 1996. 
[12] D. Bendz, N.A. Paxéus, T.R. Ginn, F.J. Loge, 
―Occurrence and fate of pharmaceutically active compounds 
in the environment, a case study,‖ Journal of Hazardous 
Material,122, pp. 195-204, 2005. 
[13] G. Ohlenbusch, M.U. Kumke, F.H. Frimmel, Sorption of 
phenols to dissolved organic matter investigated by solid 
phase micro extraction, Science of the Total Environment, 
253, pp. 63-74, 2000. 
[14] M. Khamis, R. Karaman, F. Ayyash, A. Qtait, O. Deeb 
and A. Manssra, ―Efficiency of Advanced Membrane 
Wastewater Treatment Plant towards Removal of Aspirin, 
Salicylic Acid, Paracetamol and p-Aminophenol,‖ Journal of 
Environmental Science and Engineering, 5, pp. 121-137, 
2011. 
[15] A. Goodman-Hilman, T. Rall, A. Nier, P. Taylor, ―The 
Pharmacological Basis of Therapeutics,‖ McGraw-Hill, New 
York, 1996. 
A. [16] A. Schepers, M.M. Pires Nuno, D. Eefting, M.R. de 
Vries, J.H. van Bockel, P.H.A. Quax, ―Short-term 
dexamethasone treatment inhibits vein graft thickening in 
hypercholesterolemic ApoE3Leiden transgenic mice,‖ 
Journal of Vascular Surgery, 43, pp. 809-815, 2006. 
[17] D.W. Muller, G. Golomb, D. Gordon, R.J. Levy, ―Site-
specific dexamethasone delivery for the prevention of 
neointimal thickening after vascular stent placement,‖ 
Coronary Artery Disease, 5, pp. 435-442, 1994. 
[18] E.P. Strecker, A. Gabelmann, I. Boos, C. Lucas, Z. Xu , 
J. Haberstroh, N. Freudenberg, H. Stricker, M. Langer, E. 
Betz, ―Effect on intimal hyperplasia of dexamethasone 
released from coated metal stents compared with non-coated 
stents in canine femoral arteries,‖ Cardiovascular Intervent 
Radiology, 21, pp. 487-496, 1998. 
[19] R. Hoffmann, R. Langenberg, P. Radke, A. Franke, R. 
Blindt, J. Ortlepp, J.J. Popma, C. Weber, P. Hanrath, 
―Evaluation of a high-dose dexamethasone-eluting stent,‖ 
American Journal of Cardiology, 94, pp. 193-195, 2004. 
[20] British Pharmacopeia, Revised edition, British 
Pharmacopoeia Commission, London, 2007. 
[21] Martindale: The Extra Pharmacopoeia, 30th ed., 
Pharmaceuticals Press, London, 1993, p 728. 
[22] Martindale: The Extra Pharmacopoeia, J. E. F. Reynolds 
ed., Royal Pharmaceutical Society, London, 1996,pp. 700-
706. 
[23] J.C. Cloyd, R.L. Lalonde, T.E. Beniak, and G.D. 
Novack, ―A single-blind crossover comparison of the 
pharmacokinetics effects of a new diazepam rectal gel with 
intravenous Diazepam,‖ Epilepsia, 39, pp. 520-526, 1998. 
[24] E. Rey, J.M. Treluyer, and G. Pons, ―Pharmacokinetic 
optimization of benzodiazepine therapy for acute seizures. 
Focus on delivery routes,‖ Clinical Pharmacokinetics, 36, pp. 
409-424, 1999. 
[25] M. Winkler, J.R Lawrence, and T.R. Neu, ―Selective 
degradation of ibuprofen and clofibric acid in two model 
river biofilm systems, ‖ Water Research, 35, pp. 3197-3205, 
2001. 
[26] R. Henschel, A. Wenzel, M. Diedrich, and A. Fliedner, 
―Environmental hazard assessment of pharmaceuticals,‖ 
Regulatory Toxicology and Pharmacology, 25, pp. 220-225, 
1997. 
[27] M. Khamis, R. Karaman, M. Qurie, J. Abbadi, S. 
Nusseibeh, A. Manassra, S. Nir, ―Performance of micelle-
clay filters for removing pollutants and bacteria from tertiary 
treated wastewater,‖ Journal of Environmental Science and 
Engineering, 1, pp. 160-168, 2012. 
[28] O.A.H. Jones, N. Voulvoulis, and J.N. Lester, ―Human 
pharmaceuticals in wastewater treatment processes,‖ Critical 
Review of Environmental Science and Technology, 35, 401-
427, 2005. 
[29] D.J. Greenblatt, I.S. Harmatz, H. Friedman, A. 
Locniskar, and R.I.A. Shader, ―large-sample study of 
diazepam pharmacokinetics,‖ Therapeutic drug 
monitoring.,11, pp. 652 -657, 1989. 
[30] E. Charles, ―The photodegradation of diazepam in 
human and its metabolites,‖ PhD diss., University of 
Plymouth, 2007.  
[31] United States Environmental Protection Agency 
(USEPA). “Wastewater Treatment Manuals: Primary, 
Secondary and Tertiary treatment,” Author: Washington, DC, 
1997. 
[32] V. Laurian, I. Silvia, M. Dana, A. Marcela, M. Daniela-
Lucia, ―Determination of spironolactone and canrenone in 
human plasma by high-performance liquid chromatography 
with mass spectrometry detection.‖ Croatica Chemica Acta , 
84(3), pp. 361-366, 2011. 
Impact Factor 3.582   Case Studies Journal ISSN (2305-509X) – Volume 4, Issue 5 – May-2015 
http://www.casestudiesjournal.com  Page 21 
[33] S.A. Doggrell, L. Brown, ―The spironolactone 
renaissance.‖ Expert Opinion on Investigational Drugs, 10, 
pp. 243-254, 2001. 
[34] S.J. Lloyd, V.F. Mauro, ―Spironolactone in the treatment 
of congestive heart failure.‖ Annals of Pharmacotherapy, 34, 
pp. 1336-1340, 2000. 
[35] B. Noerr, ―Spironolactone.‖ Neonatal Network, 18, pp. 
43-46, 1999. 
[36] V.D. Gupta,; C.W. Gibbs, A.G. Ghanekar, ―Stability of 
pediatric liquid dosage forms of ethacrynic acid, 
indomethacin, methyldopate hydrochloride, prednisone and 
spironolactone.‖ American Journal of Hospital Pharmacy, 35, 
pp.1382-1385, 1978.  
[37] L.K. Mathur, A. Wickman, ―Stability of 
extemporaneously compounded spironolactone suspensions.‖ 
American Journal of Hospital Pharmacy, 46, pp. 2040-2042, 
1989. 
[38] Y. Pramar, V.D. Gupta, C. Bethea, ―Development of a 
stable oral liquid dosage form of spironolactone,‖ Journal of 
Clinical Pharmacy and Therapeutics, 17, pp. 245-248, 1992. 
[39] M.C. Nahata, R.S. Morosco, T.F. Hipple, ―Stability of 
spironolactone in an extemporaneously prepared suspension 
at two temperatures,‖ Annals of Pharmacotherapy, 27, pp. 
1198-1199, 1993. 
[40] Jr. L.V. Allen, M.A. Ericson, ―Stability of ketoconazole, 
metolazone, metronidazole, procainamide hydrochloride, and 
Spironolactone in extemporaneously compounded oral 
liquids,‖ American Journal of Health-System Pharmacy, 53, 
pp. 2073-2078, 1996. 
[41] Jr, L.V. Allen, M.A. Ericson, ―Stability of labetalol 
hydrochloride, metoprolol tartarate, verapamil hydrochloride, 
and spironolactone with hydrochlorotiazide in 
extemporaneously compounded oral liquids,‖ American 
Journal of Health-System Pharmacy, 53, pp. 2304-2309, 
1996. 
[42] Jr. L.V. Allen, ―The art, science and technology of 
pharmaceutical compounding,‖ American Pharmaceutical 
Association, 2
nd
 ed., Washington: AphA, 2002;133-159. 
[43] Y. Pramar, V.D. Gupta, T. Zerai, ―Quantitation of 
spironolactone in the presence of canrenone using high-
performance liquid chromatography,‖ Drug Development and 
Industrial Pharmacy, 17, pp.747-761, 1991. 
[44] H. Da-Ming, Z. Tian-Zhen, C. Feng- Jie, S. Wen-Jing, Z. 
Li-Ming, Y. Meng –Yi, W. Ya-Juan, ―Simultaneous 
Identiﬁcation and Quantiﬁcation of Canrenone and 11-α-
Hydroxy-Canrenone by LC -MS and H PLC-UVD,‖ Journal 
of Biomedicine and Biotechnology, 7 pages, 2011. 
[45] L.E. Ramsay, J.R. Shelton, D. Wilkinson, M.J. Tidd, 
―Canrenone- the principal active metabolite of 
spironolactone,‖ Journal of Clinical Pharmacology, 3, pp. 
607-612, 1976. 
[46] Y.G. Mishael, T. Undabeyita, G. Rytwo, B. 
Papahadjopoulos-Sternberg, B. Rubin, S. Nir, ―Sulfometuron 
adsorption via alkylammonium cations adsorption as 
monomers and micelles on montmorillonite,‖ Journal of 
Agricultural and Food Chemistry, 50, pp. 2856-2863, 2002. 
[47] T. Polubesova, S. Nir, D. Zadaka, O. Rabinovitz, C. 
Serban, L. Groisman, ―Water purification of organic 
pollutants by optimized micelle-clay systems,‖ 
Environmental Science and Technology, 39, pp. 2369-2384, 
2005. 
[48] T. Polubesova, D. Zadaka, L. Groisman, S. Nir, ―Water 
remediation by micelle-clay system: Case study for 
tetracycline and sulfonamide antibiotics,‖ Water Research, 
40, pp. 2369-2374, 2006. 
[49] D. Zadaka, Y.G. Mishael, T. Polubesova, C. Serban. S. 
Nir, ―Modified silicates and porous glass as adsorbents for 
removal of organic pollutants from water and comparison 
activated carbons,‖ Applied Clay Science, 36, pp. 174-181, 
2007. 
 
[50] R. Karaman, M. Khamis, M. Qurie, R. Halabieh, I. 
Makharzeh, A. Nasser, A. Manassra, J. Abbadi, F. Qtait, S. 
Bufo, S. Nir, ―Removal of Diclofenac Potassium from 
Wastewater Using Clay-Micelle Complex,‖ Environmental 
Technology, 33, pp. 1279-1287, 2012. 
 
[51] S. Khalaf, F. Al-Rimawi, M. Khamis, D. Zimmerman, U. 
Shuali, S. Nir, L. Scrano, S.A. Bufo, R. Karaman, ―Efficiency 
of advanced wastewater treatment plant system and 
laboratory-scale micelle-clay filtration for the removal of 
ibuprofen residues,‖ Journal of Environmental Science and 
Health, Part B, 48, pp. 814–821, 2013. 
[52] American Public Health Association (APHA). Standard 
Methods for the Examination of Water and Wastewater, 19th 
ed. APHA, Washington, DC, 1995. 
[53] American Public Health Association (APHA). Standard 
Methods for the Examination of Water and Wastewater, 21th 
ed. APHA, Washington, DC, 2005. 
[54] J. Abbadi, R. Saleh, S. Nusseibeh, M. Qurie, M. 
Khamis, R. Karaman, L. Scrano and S.A. Bufo, ―Microbial 
Removal from Secondary Treated Wastewater Using a 
Hybrid System of Ultrafiltration and Reverse Osmosis,‖ 
Journal of Environmental Science and Engineering A1, pp. 
853-869, 2012. 
[55] T.A. Ternes, ―Occurrence of drugs in German sewage 
treatment plants and rivers,‖ Water Research, 32, pp. 3245-
60, 1998. 
[56] D. Bendz, N.A. Paxéus, T.R. Ginn, F.J. Loge, 
―Occurrence and fate of pharmaceutically active compounds 
in the environment, a case study,‖ Journal of Hazardous 
Material, 122, pp. 195-204, 2005. 
[57] Q. Chen, D. Zielinski, J. Chen, A. Koski, D. Werst, S. 
Nowak, ―A validated, stability-indicating HPLC method for 
the determination of dexamethasone related substances on 
dexamethasone-coated drug-eluting stents,‖ Journal of 
Pharmaceutical and Biomedical Analysis, 48, pp. 732-738, 
2008. 
[58] E.S. Tomlinson, J. Maggs, B.K. Park and D.J. Back, 
―Dexamethasone metabolites in Vitro: Species Differences,‖ 
The Journal of Steroid Biochemistry and Molecular Biology, 
4, pp. 62-68, 1997. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Impact Factor 3.582   Case Studies Journal ISSN (2305-509X) – Volume 4, Issue 5 – May-2015 
http://www.casestudiesjournal.com  Page 22 
   
Appendix A 
 
 
Figure 1: Flow diagram schematizing the WWTP at Al-Quds University. Sampling sites are indicated by numbers. UF/HF, hollow 
fiber ultrafiltration membrane; UF/SW, spiral wound ultrafiltration membrane; RO, reverse osmosis; GAC, granular activated 
charcoal filter. 
 
                                                                          
Figure 2: Structures of DSP (1) and its hydrolysis product dexamethasone (2). 
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Figure 3: benzodiazepines basic structure (3), and diazepam (4) chemical structure. 
 
 
Figure 4: Metabolism pathways for diazepam (4) in humans. 
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Figure 5: Chemical structure of Spironolactone (8) 
 
 
Figure 6: Chemical structure of Canrenone (CR) (9) 
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Figure 7: 11- α-hydroxylation of Canrenone by microbial transformation 
 
Figure 8: Structures of Spironolactone (8), Canrenone (9), Potassium canrenoate (11), and canrenoate (12) 
 
Figure 9: Chromatogram showing the appearance of an intense peak attributable to dexamethasone, the hydrolysis product of 
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dexamethasone sodium phosphate risen after two weeks of incubation in pure water. 
 
 
 
Figure 10: Kinetics of DSP degradation in pure water (plot a) and activated sludge (plot b). Data are reported as natural logarithm 
of concentrations (C(t)) vs. time. Initial concentration (C(0)) = 100 mg L
-1
. Plotted values are the means of three replicates; bars 
represent the standard deviations calculated for each average value. 
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Figure 11: Plot of Ln of diazepam vs. time in pure water (▲) (SD± 0.12) and in sludge (●) (SD ± 0.17). T = 25 oC, pH 7.3. 
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Figure 12: Extracted ion chromatograms (XICs) acquired by LC/ESI-FTICRMS in positive ion mode for the aqueous sample 
collected after two weeks of biodegradation from the activated sludge spiked with 100 mg L
-1
 of DSP. The ions monitored are 
displayed in each trace and correspond to the most abundant protonated moieties [M+H]
+
, using a restricted window of ±0.0010 
m/z unit centered around each selected ion (Table S1 in Supplementary material). 
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Figure 13: Chemical structures of dexamethasone biodegradation products. 17-oxodexamethasone C20H25FO3, exact MW 
332.17822 (13); 6-hydroxy dexamethasone C22H29FO6, exact MW 408.19427(14); testosterone C20H27FO3, exact MW 
334.19387(15); 3',4'-dihydroxy-10,13-dimethylspiro[1,2,6,7,8,9,12,14,15,16-deca hydro cyclo penta [a] phenanthrene-17,5'-
oxolane]-2',3,11-trione C22H28O6, exact MW 388.18804(16); [(8S,13S,14S,17S)-13-methyl-3-oxo-2,6,7,8,14,15,16,17-octahydro-
1H- clopenta[a]phenanthren-17-yl] acetate C20H24O3, exact MW 312.17200 (17); (8S,13S,14S,17R)-17-ethynyl-17-hydroxy-13-
methyl-1,2,6,7,8,14,15,16-octahydrocyclopenta[a]phenanthren-3-one C20H22O2, exact MW 294.16143(18); [6-Fluoro-11,14,17,21-
tetrahydroxy-16-methylpregn-4-ene-3,20-dione C22H31O6F, exact MW 410.20992 (19). 
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Figure 14: Proposed transformation pathway for the biodegradation of dexamethasone sodium phosphate (1). 
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Figure 15: Proposed transformation pathways for dexamethasone (14). 
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Figure 16: Extracted ion chromatograms (XICs) by LC/ESI-FTICRMS acquired in positive ion mode of SP solution after one 
month of biodegradation. The ions monitored are displayed in each trace and correspond to the most abundant molecules, [M+H]
+
, 
using a restricted window of ±0.0010 m/z unit centered around each selected ion. 
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Figure 17: Chemical structure for canrenoic acid (20) 
 
 
Figure 18: Langmuir isotherms for the adsorption of DSP by micelle-clay complex (■) and by activated charcoal (◆). Dosage of 
adsorbent (0.2 g). Data reported are means of three replicates. Bars represents standard deviations of means. 
 
Appendix B 
 
Table 1: Methods used and wastewater quality parameters measured in the Al-Quds WWTP. 
Parameter measured 
Instrument used for 
analysis 
Method of analysis Reference 
pH pH-meter 3320, Jenway 
SM#4500-H+(B) (on 
site) Direct measurement as 
manufacturer procedure 
APHA 1995, 19
th
 ed. 
[52] 
Conductivity 
Conductivity meter 4320, 
Jenway 
2520-B 
Total Coliforms and 
Fecal Coliforms 
Membrane filter method 
9222-B 
9221-E 
APHA 1995, 19
th
 ed. 
Orthophosphate 
Automated ascorbic acid 
reduction 
SM# 4500-PF APHA 1995, 19
th
 ed. 
COD 
BOD5 
Hach COD reactor 
DO meter – Oxy 197 
5210-B 
5220-D 
APHA 1995, 19
th
 ed. 
NH4
+
 Nesselarization method 4500A-NH3 APHA 1995, 19
th
 ed. 
Total bacterial count 
Pour plate method after 
serial dilutions 
9215D 
APHA 2005, 21
th
 ed. 
[53] 
Solids Gravimetric methods 
2540B 
2540C 
2540D 
APHA 2005, 21
th
 ed. 
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    Table 2: Physical, chemical and biological parameters of wastewater to be treated 
. 
Parameters Results Units Parameters Results Units 
pH 7.32 ±0.01 ------ TSS 3668 ±6 mg L
-1 
 
Conductivity 2000 ±8 µSm cm
-1
 BOD 915 ±5 mg L
-1 
 
Temperature 15.5 ±0.2 °C COD 1936 ±6 mg L
-1 
 
Turbidity 4960 ±7 NTU NH4-N 59.5 ±0.1 mg L
-1 
 
DO 0.40 ±0.01 mg L
-1
 PO4-P 14.3 ±0.1 mg L
-1 
 
TS 4218 ±8 mg L
-1
 FC (E. coli) 2.9 ×10
5
 ± 0.3×10
5
 cfu/100mL 
TDS 618 ± 4 mg L
-1
 TC 6.5 ×10
6
 ± 1.3×10
6
 cfu/100mL 
Settable solids 240 ± 3 mg L
-1
 TAC  2.6 ×10
7
 ± 1.3×10
7
 cfu/100mL 
a
DO, dissolved oxygen; TS, total solid; TDS, total dissolved solids; TSS, total suspended solids; BOD, biological oxygen 
demand; COD, chemical oxygen demand; FC, fecal coliforms; TC, total coliforms; TAC, total aerobic count. 
 
Table 3: Removal of DSP and dexamethasone (Hydrolysis Product – HP) from wastewater by different treatment units in Al-Quds 
WWTP; average values of three replicates. 
Sample  description 
Sampling 
site 
as in figure 
1  
Concentration of DSP and dexamethasone (HP) 
mg L
-1
 
Means  S.D. Remaining % 
  DSP HP DSP HP 
AS spiked amount  1 1.0 1.0 
 
UF-HF 
influent 2 0.83 ± 0.05 0.81 ± 0.02 
brine produced 3 0.46 ± 0.04 0.43 ± 0.04 
effluent 4 0.31 ± 0.03 0.24 ± 0.02 37.3  29.6 
UF-SW 
brine produced 5 0.19 ± 0.02 0.17 ± 0.02  
effluent 6 0.06 ± 0.03 0.07 ± 0.04 5.3 8.6 
GAC effluent 7 b.l.d. b.l.d. ≈0.0 ≈0.0 
b.l.d. = below the limit of detection 
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Table 4: Removal of diazepam from wastewater by different treatment units in Al-Quds WWTP; average values of three 
replicates. 
Sample description 
Sampling 
point 
as in figure 1 
Concentration of DZ 
mg L
-1
 
Means  S.D. Removal % 
The initial concentration of 
Diazepam in storage tank 
1 0.98 ± 0.10  
UF-HF 
influent 2 0.84 ± 0.05  
brine produced 3 0.57 ± 0.03  
effluent 4 0.15 ± 0.02 82.1 
UF-SW 
brine 5 0.15 ± 0.04  
effluent 6 0.08 ± 0.01 90.4 
GAC effluent 7 0.05 ± 0.02 93.7 
RO 
brine 8 0.07 ± 0.01  
effluent 9 b.l.d. ≈ 100.0 
b.l.d. = below the limit of detection 
 
Table 5. Removal of SP from wastewater by different treatment units in Al-Quds WWTP; average values of 
three replicates. 
Sample description 
Sampling 
site 
Concentration of SP 
mg L
-1 
Means  S.D. Removal % 
The initial concentration of SP in 
storage tank (after addition of SP) 
1 1.1 ± 0.06  
UF-HF 
influent 2 0.83 ± 0.02  
brine produced 3 0.49 ± 0.05  
effluent 4 0.25 ± 0.01 69.9 
UF-SW 
brine 5 0.22 ± 0.02  
effluent 6 0.06 ± 0.04 92.8 
GAC effluent 7 b.l.d. ≈ 100.0 
               b.l.d. = below the limit of detection 
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Table 6: Langmuir adsorption parameters (k and Qmax) and determination coefficients (R²) obtained from the 
adsorption of DSP on the micelle-clay complex and activated charcoal. 
Adsorbent k (L mg
-1
) Qmax (mg g
-1
) R² 
Micelle-clay complex 2.795 652.1 0.9997 
Activated charcoal 0.184 103.4 0.9953 
Ratio micelle-clay/charcoal 15.2 6.3 - 
 
 
Table 7: Langmuir adsorption parameters (k and Qmax) and determination coefficients (R²) obtained from the adsorption of 
diazepam on the micelle-clay complex and activated charcoal. 
Adsorbent k (L mg
-1
) Qmax (mg g
-1
) R² 
Micelle-clay complex 5.3±0.2 31.2 ± 1.7 0.997 
Activated charcoal 3.8 ±0.3 28.9 ± 1.5 0.994 
Ratio micelle-clay/charcoal 1.4 1.1 - 
 
 
Table 3: Langmuir adsorption parameters (k and Qmax) and determination coefficients (R²) obtained from the 
adsorption of SP on the micelle-clay complex and activated charcoal. 
Adsorbent k (L mg
-1
) Qmax (mg g
-1
) k* Qmax (L g
-1
)  R² 
Micelle-clay 
complex 
3.3± 0.3 17.8± 2.5 58.7±1.5 0.935 
Activated charcoal 2.7± 0.3 10.6± 2 28.6±1.1 0.964 
 
Table 9: Removal of DSP by filtration of 1L of pure water solutions (100, 10, 1.0, 0.01 mg 
L
-1
) through laboratory filters, which included either MC or GAC mixed with excess sand at 
1:50 (w/w) ratio; means of three replicates. 
Initial 
concentration 
(mg L
-1
) 
Column type 
a
 
Average eluted 
concentration 
(mg L
-1
) 
SD 
100 MC b.l.d. - 
100 GAC 64.3 1.2 
10 MC b.l.d. - 
10 GAC 3.1 0.5 
1.0 MC b.l.d. - 
1.0 GAC 0.17 0.08 
0.01 MC b.l.d. - 
0.01 GAC b.l.d. - 
a 
Flow rate, 2 mL min
-1
; temperature, 25
 0
C; b.l.d., below the detection limit of the 
analytical method used. 
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Table 10: Removal of diazepam by filtration of 1L of  water solutions  diazepam (100, 10, 1.0, 0.01 mg L
-1
) through laboratory 
filters consisting of either micelle-clay (MC) or GAC mixed with excess sand at 1:50 (w/w) ratio; means of three replicates. 
Initial concentration 
(mg L
-1
) 
Column type
a
 Average eluted concentration 
(mg L
-1
) 
SD 
100 MC 0.7 0.1 
100 GAC 1.95 0.5 
10 MC b.l.d. - 
10 GAC 1.4 0.9 
1.0 MC b.l.d. - 
1.0 GAC 0.1 0.02 
0.01 MC b.l.d. - 
0.01 GAC b.l.d. - 
a
Flow rate, 2 mL min
-1
; temperature, 25
 0
C; b.l.d., below the detection limit of the analytical method used. 
 
 
Table 11: Removal of SP by filtration of 1L of water solutions through laboratory filters, 
which included either MC or GAC mixed with excess sand at 1:50 (w/w) ratio; means of 
three replicates. 
a
 
Initial 
concentration 
(mg L
-1
) 
Column type 
a
 
Average eluted 
concentration 
(mg L
-1
) 
SD 
100 MC 13.5 3.5 
100 GAC 24 4.2 
10 MC b.l.d. - 
10 GAC b.l.d. - 
1.0 MC b.l.d. - 
1.0 GAC b.l.d. - 
0.01 MC b.l.d. - 
0.01 GAC b.l.d. - 
a
Flow rate, 2 mL min
-1
; temperature, 25
0
C; b.l.d., below the detection limit of the 
analytical method used. 
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Supplementary Material 
 
Table S1: Compounds occurring in DSP solution (activated sludge) after 
two weeks of biodegradation, identified as [M+H]
+
 ions by LC–ESI-
FTICR/MS. 
Accurate m/z 
Formula of 
identified ions 
[M+H]
+
 
Retention 
time 
(min) 
Error 
(ppm) 
411.21808 C22H31FO6  (9) 10.42 0.80 
409.20232 C22H30FO6  (4) 10.23 0.50 
389.19595 C22H29O6 (6) 10.11 0.20 
335.20163 C20H27O3 F (5) 9.68 -0.20 
333.18619 C20H26O3F (3) 8.56 0.40 
313.17987 C20H25O3 (8) 8.59 0.15 
295.16928 C20H23O2 (7) 8.59 0.08 
 
 
Figure S1: Positive ion electrospray - IRMPD mass spectrum of degradation moiety peak at 
m/z 313. 
      :    
F: FTMS + p ESI Full ms2 313.00@0.00 mpd@100.00 [ 50.00-350.00] 
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